Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination

详细信息    查看全文

• 作者：Yi-Nan Zhang^a ; ^b ; ¹ ; Wilson Poon^a ; ^b ; ¹ ; Anthony J. Tavares^a ; ^b ; Ian D. McGilvray^c ; ^d ; Warren C.W. Chan^a ; ^b ; ^e ; ^f ; ^g ; ^{warren.chan@utoronto.ca" class="auth_mail" title="E-mail the corresponding author}
• 关键词：ACO ; Aconitylated ; ADP ; Adenine diphosphate ; ATP ; Adenine triphosphate ; Aco-HSA ; Polyaconitylated human serum albumin ; Apo ; Apolipoprotein ; ASGP ; Asialoglycoprotein ; BSA ; Bovine serum albumin ; DLPC ; Dilinoleoylphosphatidylcholine ; DLS ; Dynamic light scattering ; DOPE ; Dioleoylphosphatidyl ethanolamine ; DOTAP ; 1 ; 2Dioleoyl-3-trimethylammonium-propane ; DOX ; Doxorubicin ; ePC ; Egg yolk phosphatidylcholine ; EDX ; Electron dispersive x-ray ; EGF ; Epidermal growth factor ; FITC ; Fluorescein isothiocyanate
• 刊名：Journal of Controlled Release
• 出版年：2016
• 出版时间：28 October 2016
• 年：2016
• 卷：240
• 期：Complete
• 页码：332-348
• 全文大小：2142 K

文摘

30–99% of administered nanoparticles will accumulate and sequester in the liver after administration into the body. This results in reduced delivery to the targeted diseased tissue and potentially leads to increased toxicity at the hepatic cellular level. This review article focuses on the inter- and intra-cellular interaction between nanoparticles and hepatic cells, the elimination mechanism of nanoparticles through the hepatobiliary system, and current strategies to manipulate liver sequestration. The ability to solve the “nanoparticle-liver” interaction is critical to the clinical translation of nanotechnology for diagnosing and treating cancer, diabetes, cardiovascular disorders, and other diseases.